Table of Contents
- Key safety points
- Overview
- Forms and Bioavailability
- Evidence for Health Benefits
- Recommended Dosing
- Safety and Side Effects
- Drug Interactions
- Dietary Sources
- Mechanisms of Action
- References
Key safety points
- Valerian may add to the drowsiness caused by alcohol, benzodiazepines such as diazepam, barbiturates, opioids such as morphine, and other sedatives. Check with your doctor or pharmacist before combining them [11].
- Valerian may strengthen the sedative effect of anesthetics. Tell your surgeon and anesthetist that you take it before any operation [76].
- Valerian has been linked to rare cases of liver injury [92, 93, 94], so check with your doctor first if you have liver disease, and stop it and see your doctor if your skin or eyes turn yellow.
- Do not take valerian while pregnant or breastfeeding without your doctor's advice, and do not give it to children younger than 3 years old. Its risks in these groups have not been evaluated [11].
- A small trial found slightly reduced alertness 1 to 2 hours after a dose, so avoid driving or using machinery for the first few hours. Tests the morning after usual doses found no impairment [63, 95].
- Headache, dizziness, itching and stomach upset are the side effects most often reported in trials, but placebo groups reported them too [11].
1. Overview
Valerian (Valeriana officinalis) is a perennial plant native to Europe and Asia and naturalized in North America; its roots are used in many traditional medicine systems as a mild sedative and to help sleep [1, 11, 12]. Hippocrates described its uses, and in the 2nd century Galen prescribed it for insomnia [3, 4, 11]. In the 16th century, it was used to treat nervousness, trembling, headaches, and heart palpitations [7, 11]. During World War II, it was used in England to relieve the stress of air raids [9, 11].
Today, valerian is one of the most used herbal products for sleep problems [44]. In the United States it is sold as a dietary supplement, and dietary supplements are regulated as foods, not drugs, so premarket evaluation and approval by the FDA are not required unless specific disease prevention or treatment claims are made [11].
The genus Valeriana includes over 250 species, but V. officinalis is the species most often used in the United States and Europe [2, 5, 11]. Other names for valerian include setwall (English), Valerianae radix (Latin), Baldrianwurzel (German), and phu (Greek) [11]. Its roots contain valerenic acid and other sesquiterpenes, valepotriates, a volatile oil and GABA, among many other compounds [11, 12]. There is no scientific agreement on which constituents are active, and its effects may come from several of them acting together [11, 13].
The evidence that valerian helps sleep is mixed. Reviews call it inconclusive or find no benefit on objective sleep measures, while some trials report better self-rated sleep [11, 15, 16, 44]. Evidence for anxiety is limited and comes mainly from small studies [43, 51]. Few adverse events have been reported, but long-term safety data are not available [11].
2. Forms and Bioavailability
Active Compounds
Valerian root contains several classes of bioactive compounds, and their amounts vary with plant genetics, environment and harvest time [12, 35]:
Valerenic acids are the most studied constituents and include three main forms:
- Valerenic acid (VA): Binds a specific site on GABA-A receptors with high (nanomolar) affinity and enhances the response to GABA. A point mutation in the beta-2 or beta-3 subunit strongly reduced this effect, and in mice carrying the beta-3 mutation valerenic acid lost its anti-anxiety action [22].
- Acetoxyvalerenic acid (AVA): Binds the same receptor sites without enhancing the response to GABA [23]. In mice, adding it abolished the anti-anxiety action of valerenic acid [53].
- Hydroxyvalerenic acid (HVA): Also binds the same sites without enhancing the response to GABA [23].
In mice, an extract with a 12:1 ratio of valerenic to acetoxyvalerenic acid reduced anxiety-like behaviour at a dose four times lower than an extract with a 1:1.5 ratio, and the authors concluded that standardizing extracts to total valerenic acids is misleading [23]. In roots harvested across several seasons, valerenic acid and its derivatives peaked in February to March at 0.7-0.9% of dry weight [35].
Valepotriates (such as valtrate and isovaltrate) are unstable and break down during storage or in water [11, 19]. In laboratory tests, diene-type valepotriates such as valtrate were the most cytotoxic valerian constituents, while their breakdown products, the baldrinals, were 10- to 30-fold less toxic [24]. Stored tinctures became much less cytotoxic as their valepotriates decomposed, and valepotriates are not necessarily present in commercial preparations [11, 24].
Volatile oils give valerian its distinctive odor, which many people find unpleasant [2, 8, 11]. Their makeup varies widely between plant populations; major constituents include bornyl acetate and valerenic acid [12]. Essential oil content peaked in September at 1.2% to 2.1% of root dry weight [35].
Other constituents include GABA, which aqueous extracts contain in appreciable amounts, though whether it reaches the brain is uncertain [11, 12]. Glutamine, present in aqueous but not alcohol extracts, may cross the blood-brain barrier and be converted to GABA [11, 27]. A lignan, hydroxypinoresinol, can bind benzodiazepine receptors [12].
Supplement Forms
| Form | Description | Doses Used in Trials | Valerenic Acid Content |
|---|---|---|---|
| Standardized dry extract (capsules/tablets) | Concentrated root extract; LI 156 is the most tested | 600 mg (LI 156) | Varies; one trial extract held 2% |
| Aqueous extract | Water extract of the root | 400 mg or 450 mg | Not reported |
| Tea and tincture | Dried root steeped in water, or an alcohol extract | Not tested in the trials described here | Variable |
| Combination products | Valerian combined with hops, lemon balm, or other herbs | Varies by product | Varies |
Standardized extracts are the form most often studied in clinical trials. Several trials used LI 156 (Sedonium), a standardized dried valerian root extract, at 600 mg [11, 30, 31, 33, 63].
Root powder products have not been tested at a set dose in the trials described here.
Teas and tinctures were not tested in these trials either, and the valerenic acid content of commercial valerian products varies widely, both between samples and against their labels [34].
Combination products: valerian is sometimes combined with hops, lemon balm, or other herbs [3, 11]. Results from a combination trial cannot be credited to valerian alone.
Bioavailability and Quality Considerations
Harvest time changes the content of valerian root. In plants studied over several seasons, essential oil peaked in September, while valerenic acid and its derivatives, and the valepotriates, peaked in February to March [35].
Valepotriates break down during storage, so their content falls over time [11, 24].
Commercial products differ widely in valerenic acid content, and measured amounts often differ from label claims [34].
Because dietary supplements are not always tested for manufacturing consistency, the composition may vary considerably between manufacturing lots [11].
3. Evidence for Health Benefits
Sleep and Insomnia
Valerian is most often taken to help sleep, but the clinical evidence is mixed. Systematic reviews have called the evidence inconclusive or found no benefit, while some individual trials report modest gains in self-rated sleep [11, 15, 16, 44].
Systematic Reviews and Meta-Analyses
Taibi et al., 2007: A systematic review of 37 studies, 29 of them controlled trials, found that most showed no difference between valerian and placebo, and that none of the most recent and most rigorous trials found an effect on sleep [15]. The authors concluded that valerian is safe, with only rare adverse events, but that the evidence does not support it as a sleep aid for insomnia [15].
Stevinson and Ernst, 2000: An earlier systematic review found nine randomized, placebo-controlled, double-blind trials and concluded they were not sufficient for determining the effectiveness of valerian for sleep disorders [11, 16]. None of the studies checked the success of blinding, none calculated the sample size needed to detect an effect, only one partially controlled pre-bedtime variables [30], and only one validated its outcome measures [42]. All nine trials had flaws, but three earned the highest quality rating (5 on a scale of 1 to 5) and are described below [11].
Bent et al., 2006: A meta-analysis of 16 randomized, placebo-controlled studies with 1,093 patients found that most had significant methodological problems and that doses and preparations varied widely [17]. In the 6 studies that reported sleep quality as improved or not, valerian helped (relative risk of improved sleep 1.8, 95% confidence interval 1.2 to 2.9), but there was evidence of publication bias [17]. The authors concluded that valerian might improve sleep quality without producing side effects [17].
Shinjyo et al., 2020: A systematic review of 60 studies (n=6,894) suggested that inconsistent results may stem from the variable quality of herbal extracts, and that the whole root or rhizome may give more reliable effects [43]. It found no severe adverse events in people aged between 7 and 80 years [43].
Valente et al., 2024: An umbrella review of eight systematic reviews found no evidence that valerian works for insomnia, although it appeared to improve self-rated sleep quality with no demonstrated gain on objective measures [44]. It found a good safety profile and described the existing trials as few, heterogeneous and of low methodological quality [44].
Individual Clinical Trials
Leathwood et al., 1982 (n=128, highest-quality trial): In a repeated-measures design, 128 volunteers took 400 mg of an aqueous valerian extract, a commercial preparation containing 60 mg valerian and 30 mg hops, and a placebo, each three times in random order on nine non-consecutive nights [11]. Compared with placebo, the valerian extract improved self-rated sleep latency and sleep quality, and the gain in sleep quality was clearest among people who considered themselves poor or irregular sleepers; night awakenings changed little [42]. The valerian-hops product changed only one measure: more people reported feeling sleepier than normal the next morning [42]. Having insomnia was not required to take part, and the study had a participant withdrawal rate of 22.9% [11].
Leathwood and Chauffard, 1985 (n=8, highest-quality trial): Eight volunteers with mild insomnia (usually trouble falling asleep) wore wrist activity meters and filled in morning questionnaires [11, 45]. They took 450 mg or 900 mg of an aqueous valerian extract or a placebo, one sample each night, Monday through Thursday, for 3 weeks (12 nights in total) [11]. The 450 mg dose reduced average sleep latency from about 16 to 9 minutes, similar to a prescription benzodiazepine, and participants rated sleep latency as 4.3 on a 9-point scale after 450 mg versus 4.9 after placebo [11]. The 900 mg dose did not significantly shorten sleep latency, and participants noted more sleepiness the next morning [11]. The 7-minute reduction is probably not clinically significant, and the small sample makes the results hard to generalize [11].
Vorbach et al., 1996 (n=121, highest-quality trial): In this 28-day trial, 121 people with documented nonorganic insomnia took 600 mg of a standardized dried valerian root extract (LI 156, Sedonium) or placebo [11, 30]. After 28 days, the valerian group had fewer insomnia symptoms on every assessment tool, and the gap between valerian and placebo widened between the day 14 and day 28 assessments [11, 30].
Dorn, 2000 (n=75): A randomized, double-blind trial gave 75 outpatients with nonorganic insomnia either two 300 mg tablets of the LI 156 extract or two 5 mg tablets of oxazepam (a benzodiazepine) daily, 30 minutes before bed, for 28 days [31]. Sleep quality improved in both groups with no significant difference between them, and the authors described valerian's side-effect profile as more favourable [31]. The study was designed to show superiority, so its results cannot show that the two treatments work equally well [11].
Donath et al., 2000 (n=16, polysomnography): In a randomized, double-blind, placebo-controlled crossover trial, people with insomnia confirmed by sleep studies took 600 mg of LI 156 as a single dose and for 14 days, with sleep measured by polysomnography [11]. Valerian had no effect on any of the 15 objective or subjective measures except one [11]. It shortened the time to reach slow-wave (deep) sleep: 13.5 minutes on valerian versus 21.3 minutes on placebo [33]. Because only that endpoint differed, chance may explain it [11]. There were 3 adverse events during valerian treatment versus 18 during placebo [33].
Shekhar et al., 2024 (n=80): In an 8-week trial, 80 young adults with mild insomnia symptoms took a capsule containing 200 mg of a valerian root extract with 2% total valerenic acid or placebo [46]. Among the 72 who completed it, the valerian group improved more on a sleep quality score (PSQI) and on wrist-measured sleep latency, sleep time and sleep efficiency; in a sleep-laboratory subset of 20 per group, total sleep time, sleep latency and sleep efficiency also improved by day 56 [46]. The extract's maker, OmniActive Health Technologies, funded the study [46].
Taavoni et al., 2011 (n=100, postmenopausal women): In a triple-blind trial, 100 women aged 50 to 60 years, past menopause and with insomnia, took 530 mg of concentrated valerian extract or placebo twice a day for 4 weeks [49]. Sleep quality improved more on valerian: 30% of the valerian group and 4% of the placebo group showed better sleep quality [49].
Taibi et al., 2009 (n=16, older women): In a crossover trial, 16 older women with insomnia took 300 mg of concentrated valerian extract or placebo 30 minutes before bed for 2 weeks [91]. Valerian did not improve sleep latency, time awake after falling asleep, sleep efficiency or self-rated sleep quality, measured by polysomnography, actigraphy and sleep logs [91].
Synthesis
Valerian may modestly improve self-rated sleep quality for some people, but objective measures mostly show no benefit, and the most rigorous recent trials found no effect [15, 44]. In one trial the gap over placebo grew between day 14 and day 28, so any benefit may take several weeks to appear [30]. Trials were often small, used different amounts and sources of valerian, measured different outcomes, or did not account for high withdrawal rates, which leaves the evidence inconclusive [11].
Anxiety and Stress
Valerian is promoted for daytime anxiety and stress, and valerenic acid's action on GABA-A receptors makes an anti-anxiety effect plausible [22]. Clinical evidence comes mainly from small studies. A 2020 meta-analysis that included 8 anxiety studies (535 people) concluded that valerian could help prevent disorders linked to poor sleep, such as anxiety, but it tied inconsistent results across studies to variable extract quality [43].
Andreatini et al., 2002 (n=36): In a 4-week pilot trial, 36 outpatients with generalized anxiety disorder took valepotriates (a valerian extract; mean daily dose 81.3 mg), diazepam (mean daily dose 6.5 mg) or placebo, 12 per group [51]. The groups did not differ on the main anxiety score (HAM-A), and all three improved [51]. Only the diazepam and valepotriate groups improved on the psychic (mental) symptoms of anxiety, which the authors called a preliminary signal given the small groups [51].
Kennedy et al., 2006 (valerian and lemon balm combination): In a crossover study, 24 healthy volunteers took single doses of 600 mg, 1,200 mg and 1,800 mg of a standardized product combining lemon balm and valerian extracts, and a placebo, before a laboratory stress test [52]. The 600 mg dose eased the rise in anxiety ratings, but 1,800 mg increased anxiety in one testing session, and all three doses worsened performance on one attention task (the Stroop test) [52]. These results belong to the combination, not to valerian alone.
Preclinical evidence: In mice, valerenic acid and valerenol reduced anxiety-like behaviour, an effect absent in mice with a mutated beta-3 GABA-A receptor subunit [22]. Adding acetoxyvalerenic acid abolished valerenic acid's effect, and the valerian extract did not bind benzodiazepine sites [53]. An extract with a high ratio of valerenic to acetoxyvalerenic acid reduced anxiety at a lower dose than one with a low ratio [23].
Synthesis
The evidence for valerian as an anxiolytic rests mainly on small pilot studies with methodological limitations. The Kennedy 2006 dose findings came from a valerian and lemon balm combination, so they do not show how valerian alone behaves at different doses [52]. Larger, well-designed trials of valerian alone are needed before it can be recommended for anxiety.
Restless Legs Syndrome
The evidence that valerian helps restless legs syndrome (RLS) is weak, and a US sleep medicine guideline suggests against it [55].
Cuellar and Ratcliffe, 2009 (n=37): In an 8-week triple-blind trial, 37 people aged 36 to 65 years with RLS took 800 mg of valerian or placebo [54]. Both groups reported improvement in RLS symptoms and sleep [54]. The authors reported benefit only within the valerian group, in a nested analysis of 17 people that compared sleepier participants (Epworth score of 10 or greater) with less sleepy ones [54].
The American Academy of Sleep Medicine's 2025 guideline suggests against the use of valerian for RLS in adults (conditional recommendation, very low certainty of evidence) [55].
Menopausal Hot Flashes
Mirabi and Mojab, 2013 (n=68): In a double-blind trial, 68 menopausal women with hot flashes took 255 mg valerian capsules or starch-filled placebo capsules 3 times a day for 8 weeks [56]. Hot flash severity and frequency fell on valerian but not on placebo [56]. This is a single trial, and it needs replication before it can guide treatment.
Other Traditional Uses
Valerian has historically been used for gastrointestinal spasms and distress, epileptic seizures, and attention deficit hyperactivity disorder (ADHD). However, the scientific evidence is too thin to support valerian for these conditions [11]. Valerian and related plants are used in the traditional medicine of many cultures as mild sedatives and tranquillizers and to help people fall asleep [12].
4. Recommended Dosing
Dosing by Indication
For insomnia (primary use):
- Standardized extract: The most studied dose is 600 mg of the LI 156 dried root extract [11, 30]. One trial gave it 30 minutes before bed [31]. An aqueous extract helped at 400 mg in one trial [42]. A smaller trial used 450 mg [11]. Other trials with positive results used 530 mg of concentrated extract twice a day [49], or a 200 mg extract with 2% valerenic acid [46]. A 300 mg dose of concentrated extract did not help older women [91].
- Root powder and tea: No trial described here tested a set dose of root powder or tea, and the valerenic acid content of commercial products varies widely [34].
- Duration: In the Vorbach 1996 trial, the gap over placebo grew between day 14 and day 28, so any benefit may take several weeks of nightly use to appear [30].
For anxiety (speculative use):
- No dose is established. The Andreatini pilot trial used valepotriates at a mean daily dose of 81.3 mg [51]; the Kennedy 2006 study tested a valerian and lemon balm combination, not valerian alone [52].
For menopausal hot flashes:
- The single positive trial used 255 mg valerian capsules 3 times a day for 8 weeks [56]. This requires replication.
Valerenic Acid Targets
No trial has set a target daily amount of valerenic acid. An analysis of 14 commercial products found wide variation in valerenic acid content between samples and against their labels [34]. Tablets in one interaction study had a total valerenic acid content of 5.51 mg/tablet [80], while the Shekhar trial's extract held 2% [46]. Mouse studies suggest the balance between valerenic and acetoxyvalerenic acid matters, so a label's total valerenic acid figure may mislead [23, 53].
How to Read a Supplement Label
Valerian supplements are made from the roots, rhizomes and stolons of Valeriana officinalis [11]. Labels may state a valerenic acid content, but amounts measured in commercial products often differ from label claims [34]. Composition can also vary between manufacturing lots [11]. Independent testers such as ConsumerLab.com and Labdoor publish product test results.
Comparison with Evidence-Based Sleep Alternatives
For those seeking evidence-based sleep support, it is worth noting that other compounds have stronger clinical evidence than valerian:
- Melatonin (0.3-0.5 mg) has a well-established mechanism for circadian rhythm regulation
- Magnesium: a 2021 review pooled 2 small trials, both using 500 to 729 mg a day of elemental magnesium, given as magnesium oxide; people fell asleep about 17 minutes sooner than with placebo, but the evidence was rated low to very low quality
- Glycine (2,500-3,000 mg) has demonstrated improved subjective sleep quality in three RCTs
From the MicroVitamin range
Sleep combines the three alternatives listed above in one nightly serving: 0.8 mg of sustained-release melatonin, 126 mg of fully chelated magnesium bisglycinate and 2,400 mg of glycine. Each works through a different mechanism, and this section rates their clinical evidence above valerian's. Sleep is non-habit-forming and designed not to leave you groggy in the morning. See Sleep
5. Safety and Side Effects
General Safety Profile
Few adverse events attributable to valerian have been reported in clinical studies, but long-term safety data are not available [11]. Reviews describe valerian as safe, with only rare adverse events [15, 44].
In animal tests, a water extract of valerian root showed no genotoxicity, caused no deaths in mice at 96 g/kg of body weight, and had no observed adverse effects in rats, including pregnant rats, at the highest dose tested, 14 g/kg of body weight [97].
Reported Adverse Effects
Common (mild):
- Headache
- Dizziness
- Pruritus (itching)
- Gastrointestinal disturbances
These are the effects most often reported in clinical trials, but similar effects were also reported for placebo [11].
Next-morning effects: In one study, 900 mg of valerian increased sleepiness the next morning [11]. In a trial of 102 volunteers, single and 14-day evening doses of 600 mg of LI 156 did not impair reaction time, alertness or concentration the morning after [63]. Another trial found no next-morning impairment after a valerian-only syrup or a valerian and hops tablet [95].
Mental function and driving: A single 1,600 mg dose did not impair driving-simulator performance or field sobriety tests, though the authors noted the study may have been underpowered for some measures [96]. Tests 1 to 2 hours after a valerian-only syrup found a very slight drop in vigilance, and the authors advised expecting slight impairment in the first few hours after a dose [95]. Avoid driving or using machinery for the first few hours after taking valerian. In the Kennedy 2006 study, all three doses of a valerian and lemon balm combination worsened performance on one attention task [52].
Valepotriate Safety
Valepotriates, which are not necessarily present in commercial preparations, had cytotoxic activity in vitro but were not carcinogenic in animal studies [11, 64, 65, 66, 24]. Their cytotoxicity fell as they decomposed during storage [24]. In rats, the authors judged oral valepotriates harmless to pregnant mothers and their offspring, although the highest doses increased delayed bone formation in the fetuses [66].
Hepatotoxicity
Valerian has been linked to rare cases of clinically apparent liver injury [92]. Case reports describe valerian-associated hepatitis [93, 94], and an earlier report described liver toxicity from herbal remedies [68]. Some sleep products combine valerian with other herbs that carry their own liver warnings, so check the full ingredient list.
If you have liver disease, check with your doctor before taking valerian. Stop taking it and see your doctor if your skin or eyes turn yellow.
Withdrawal and Dependency
One case report described cardiac complications and delirium associated with stopping valerian root [71]. A review of herbal medicines in surgery warns of potentially serious problems linked to both taking and stopping these herbs, so tell your doctor or anesthetist that you take valerian before surgery [76].
Overdose
In the first reported valerian overdose, at about 20 times the recommended dose, symptoms were mild and resolved within 24 hours [73]. In a case of attempted suicide with a massive overdose, the symptoms could not be clearly attributed to valerian [11].
Special Populations
Pregnancy and nursing: Pregnant or breastfeeding women should not take valerian without medical advice, because its possible risks to the fetus or infant have not been evaluated [11, 74]. Studies in pregnant rats found little or no harm to the offspring [66, 97], but the risks in people have not been studied.
Children: Children younger than 3 years old should not take valerian because its possible risks at this age have not been evaluated [11, 74]. A review covering people aged 7 to 80 years found no severe adverse events linked to valerian [43].
Pre-surgical patients: Valerian may strengthen the sedative effect of anesthetics [76]. A review of herbal medicines in surgery advises doctors to ask about and record herbal medicine use before an operation, so tell your surgeon and anesthetist if you take valerian [76].
6. Drug Interactions
Valerian may add to the effects of sedative medicines and supplements [11, 77]. Laboratory studies suggest it can inhibit a liver enzyme that breaks down many drugs, but a study in people found little effect [34, 80].
Additive Sedation (Primary Concern)
Valerian might have additive therapeutic and adverse effects if taken with sedatives, other medications, or herbs and supplements with sedative properties [11, 77]. Check with your doctor or pharmacist before combining valerian with any of these:
| Drug/Substance | Examples | Risk |
|---|---|---|
| Benzodiazepines | Alprazolam (Xanax), diazepam (Valium), lorazepam (Ativan), triazolam (Halcion) | Additive sedation and drowsiness [11, 77] |
| Barbiturates and CNS depressants | Phenobarbital (Luminal), morphine, propofol (Diprivan) | Enhanced CNS depression [11, 77] |
| Alcohol | Beer, wine and spirits | Possible additive sedation [11] |
| General anesthetics | Various | May strengthen the sedative effect of anesthetics [76] |
| Sedative dietary supplements | St. John's wort, kava, melatonin | Additive therapeutic and adverse sedative effects [11, 77] |
Individuals taking any of these medications or supplements should discuss the use of valerian with their healthcare providers [11].
Pharmacokinetic Interactions (CYP450)
In laboratory tests, extracts from 14 commercial valerian products markedly inhibited cytochrome P450 3A4 (CYP3A4), an enzyme that breaks down many drugs, and the P-glycoprotein drug transporter [34]. In people, the effect looks small. In 12 healthy volunteers, two 500-mg valerian tablets (1000 mg) nightly for 14 days had no effect on CYP2D6 activity [80]. The peak blood level of alprazolam, a CYP3A4 probe drug, rose modestly, but its other measures did not change, and the authors judged clinically significant effects on drugs cleared by CYP2D6 or CYP3A4 unlikely at typical doses [80].
Regulatory Guidance
In the United States, valerian is regulated as a dietary supplement, not a drug, so the FDA does not evaluate or approve it before sale [11].
Laboratory Tests
Although valerian has not been reported to influence laboratory tests, this has not been rigorously studied [3, 74, 77].
7. Dietary Sources
Valerian is not a nutrient obtained from the diet in the way that vitamins and minerals are. It is strictly an herbal supplement derived from the roots and rhizomes of the Valeriana officinalis plant.
Plant Distribution and Habitat
Valeriana officinalis is a perennial plant native to Europe and Asia and naturalized in North America [1, 11].
Harvesting and Preparation
Supplements are made from the roots, rhizomes (underground stems), and stolons (horizontal stems) [11]. Dried roots are prepared as teas or tinctures, and dried plant materials and extracts are put into capsules or tablets [3, 11]. Harvest time changes the content: essential oil peaked in September, while valerenic acids and valepotriates peaked in February to March [35].
Traditional Use in Other Systems of Medicine
- Traditional Chinese medicine: Valerian root was used for restlessness of the heart and mind, palpitations and insomnia linked to low mood [97].
- Other species: Valeriana wallichii and Valeriana edulis are also used in herbal medicine for their mild sedative properties [24].
8. Mechanisms of Action
Valerian's pharmacological effects are thought to arise from multiple mechanisms, none of which is fully understood. It is likely that there is no single active compound and that valerian's effects result from multiple constituents acting independently or synergistically [11, 13].
GABA System Modulation
The most studied mechanism involves modulation of the gamma-aminobutyric acid (GABA) system. GABA is the primary inhibitory neurotransmitter in the brain, and increased GABAergic activity produces sedation and anxiolysis.
Valerenic acid as allosteric modulator: Valerenic acid binds a specific site on GABA-A receptors and enhances their response to GABA; in mice, receptors containing the beta-3 subunit carry its anti-anxiety effect [22]. A valerian extract did not bind the benzodiazepine sites in rat brain tissue [53].
GABA release and reuptake inhibition: In vitro studies using synaptosomes suggest that valerian extract may cause GABA to be released from brain nerve endings and then block GABA from being taken back into nerve cells, increasing GABA availability in the synaptic cleft [86].
GABA degradation inhibition: Valerenic acid inhibits an enzyme that breaks down GABA in the brain [11, 12].
Direct GABA content: Valerian extracts contain GABA in quantities sufficient to theoretically cause a sedative effect, but whether this GABA can cross the blood-brain barrier to contribute to valerian's sedative effects is not known [11]. In rat brain tissue, the extracts' GABA and other amino acids explained their binding to GABA-A receptors but not their sedative effect [27]. Glutamine, present in aqueous but not in alcohol extracts, may cross the blood-brain barrier and be converted to GABA, providing an alternative pathway [11, 27].
Volatile Oil Sedation
The second major category of proposed active constituents comprises the volatile oils, including valerenic acid and its derivatives. These have demonstrated sedative properties in animal studies [13, 21]. However, valerian extracts with very little of these components also have sedative properties, making it probable that other components contribute to or are responsible for these effects [88].
Valepotriate Activity
Valepotriates and their derivatives are active as sedatives in animal models, but their instability and rapid degradation in storage or aqueous environments make their contribution to clinical effects difficult to assess [12, 19]. Their practical relevance to commercial preparations is uncertain.
Levels of Variability
Levels of these bioactive constituents vary significantly among plants depending on when the plants are harvested, resulting in marked variability in the amounts found in valerian preparations [35]. Variable extract quality may be one reason why clinical trial results have been inconsistent [43].
9. References
[1] Wichtl M, ed. "Valerianae radix." In: Bisset NG, trans-ed. Herbal Drugs and Phytopharmaceuticals: A Handbook for Practice on a Scientific Basis. Boca Raton, FL: CRC Press, 1994: 513-516.
[2] Schulz V, Hansel R, Tyler VE. "Valerian." In: Rational Phytotherapy. 3rd ed. Berlin: Springer, 1998: 73-81.
[3] Blumenthal M, Goldberg A, Brinckmann J, eds. "Valerian root." In: Herbal Medicine: Expanded Commission E Monographs. Newton, MA: Integrative Medicine Communications, 2000: 394-400.
[4] Turner W. "Of Valerianae." In: Chapman GTL, McCombie F, Wesencraft A, eds. A New Herbal, Parts II and III. Cambridge: Cambridge University Press, 1995: 464-466, 499-500, 764-765.
[5] Davidson JRT, Connor KM. "Valerian." In: Herbs for the Mind: Depression, Stress, Memory Loss, and Insomnia. New York: Guilford Press, 2000: 214-233.
[7] Culpeper N. "Garden valerian." In: Culpeper's Complete Herbal. New York: W. Foulsham, 1994: 295-297.
[8] Pereira J. "Valeriana officinalis: common valerian." In: Carson J, ed. The Elements of Materia Medica and Therapeutics. 3rd ed. Philadelphia: Blanchard and Lea, 1854: 609-616.
[9] Grieve M. "Valerian." In: A Modern Herbal. New York: Hafner Press, 1974: 824-830. (WWII usage).
[11] National Institutes of Health, Office of Dietary Supplements. "Valerian — Health Professional Fact Sheet." Updated March 15, 2013. https://ods.od.nih.gov/factsheets/Valerian-HealthProfessional/
[12] Houghton PJ. "The scientific basis for the reputed activity of valerian." J Pharm Pharmacol. 1999;51:505-512. https://pubmed.ncbi.nlm.nih.gov/10411208/
[13] Hendriks H, Bos R, Allersma DP, Malingre M, Koster AS. "Pharmacological screening of valerenal and some other components of essential oil of Valeriana officinalis." Planta Med. 1981;42:62-68. https://pubmed.ncbi.nlm.nih.gov/7255569/
[15] Taibi DM, Landis CA, Petry H, Vitiello MV. "A systematic review of valerian as a sleep aid: safe but not effective." Sleep Med Rev. 2007;11(3):209-230. https://pubmed.ncbi.nlm.nih.gov/17517355/
[16] Stevinson C, Ernst E. "Valerian for insomnia: a systematic review of randomized clinical trials." Sleep Med. 2000;1:91-99. https://pubmed.ncbi.nlm.nih.gov/10767649/
[17] Bent S, Padula A, Moore D, Patterson M, Mehling W. "Valerian for sleep: a systematic review and meta-analysis." Am J Med. 2006;119(12):1005-1012. https://pubmed.ncbi.nlm.nih.gov/17145239/
[19] Bos R, Woerdenbag HJ, Hendriks H, et al. "Analytical aspects of phytotherapeutic valerian preparations." Phytochem Anal. 1996;7:143-151.
[21] Hendriks H, Bos R, Woerdenbag HJ, Koster AS. "Central nervous depressant activity of valerenic acid in the mouse." Planta Med. 1985;1:28-31. https://pubmed.ncbi.nlm.nih.gov/4011750/
[22] Benke D, Barberis A, Kopp S, et al. "GABA-A receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts." Neuropharmacology. 2009;56(1):174-181. https://pubmed.ncbi.nlm.nih.gov/18602406/
[23] Felgentreff F, Becker A, Meier B, Brattstrom A. "Valerian extract characterized by high valerenic acid and low acetoxy valerenic acid contents demonstrates anxiolytic activity." Phytomedicine. 2012;19(13):1216-1222. https://pubmed.ncbi.nlm.nih.gov/22944521/
[24] Bos R, Hendriks H, Scheffer JJC, Woerdenbag HJ. "Cytotoxic potential of valerian constituents and valerian tinctures." Phytomedicine. 1998;5(3):219-225. https://pubmed.ncbi.nlm.nih.gov/23195845/
[27] Cavadas C, Araujo I, Cotrim MD, et al. "In vitro study on the interaction of Valeriana officinalis L. extracts and their amino acids on GABAA receptor in rat brain." Arzneimittel-Forschung Drug Research. 1995;45:753-755. https://pubmed.ncbi.nlm.nih.gov/8573216/
[30] Vorbach EU, Gortelmeyer R, Bruning J. "Treatment of insomnia: effectiveness and tolerance of a valerian extract [in German]." Psychopharmakotherapie. 1996;3:109-115.
[31] Dorn M. "Valerian versus oxazepam: efficacy and tolerability in nonorganic and nonpsychiatric insomniacs: a randomized, double-blind, clinical comparative study [in German]." Forschende Komplementärmedizin und Klassische Naturheilkunde. 2000;7:79-84. https://pubmed.ncbi.nlm.nih.gov/10899744/
[33] Donath F, Quispe S, Diefenbach K, Maurer A, Fietze I, Roots I. "Critical evaluation of the effect of valerian extract on sleep structure and sleep quality." Pharmacopsychiatry. 2000;33:47-53. https://pubmed.ncbi.nlm.nih.gov/10761819/
[34] Lefebvre T, Foster BC, Drouin CE, et al. "In vitro activity of commercial valerian root extracts against human cytochrome P450 3A4." J Pharm Pharm Sci. 2004;7(2):265-273. https://pubmed.ncbi.nlm.nih.gov/15367385/
[35] Bos R, Woerdenbag HJ, van Putten FMS, Hendriks H, Scheffer JJC. "Seasonal variation of the essential oil, valerenic acid and derivatives, and valepotriates in Valeriana officinalis roots and rhizomes, and the selection of plants suitable for phytomedicines." Planta Med. 1998;64:143-147. https://pubmed.ncbi.nlm.nih.gov/9556440/
[42] Leathwood PD, Chauffard F, Heck E, Munoz-Box R. "Aqueous extract of valerian root (Valeriana officinalis L.) improves sleep quality in man." Pharmacol Biochem Behav. 1982;17:65-71. https://pubmed.ncbi.nlm.nih.gov/7122669/
[43] Shinjyo N, Waddell G, Green J. "Valerian root in treating sleep problems and associated disorders — a systematic review and meta-analysis." J Evid Based Integr Med. 2020;25:2515690X20967323. https://pubmed.ncbi.nlm.nih.gov/33086877/
[44] Valente V, Machado D, Jorge S, et al. "Does valerian work for insomnia? An umbrella review of the evidence." Eur Neuropsychopharmacol. 2024;82:6-28. https://pubmed.ncbi.nlm.nih.gov/38359657/
[45] Leathwood PD, Chauffard F. "Aqueous extract of valerian reduces latency to fall asleep in man." Planta Med. 1985;2:144-148. https://pubmed.ncbi.nlm.nih.gov/4034730/
[46] Chandra Shekhar H, Joshua L, Thomas JV. "Standardized extract of Valeriana officinalis improves overall sleep quality in human subjects with sleep complaints: a randomized, double-blind, placebo-controlled, clinical study." Adv Ther. 2024;41(1):246-261. https://pubmed.ncbi.nlm.nih.gov/37899385/
[49] Taavoni S, Ekbatani N, Kashaniyan M, et al. "Effect of valerian on sleep quality in postmenopausal women: a randomized placebo-controlled clinical trial." Menopause. 2011;18(9):951-955. https://pubmed.ncbi.nlm.nih.gov/21775910/
[51] Andreatini R, Sartori VA, Seabra ML, Leite JR. "Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study." Phytother Res. 2002;16(7):650-654. https://pubmed.ncbi.nlm.nih.gov/12410546/
[52] Kennedy DO, Little W, Haskell CF, Scholey AB. "Anxiolytic effects of a combination of Melissa officinalis and Valeriana officinalis during laboratory induced stress." Phytother Res. 2006;20(2):96-102. https://pubmed.ncbi.nlm.nih.gov/16444660/
[53] Becker A, Felgentreff F, Schröder H, et al. "The anxiolytic effects of a Valerian extract is based on valerenic acid." BMC Complement Altern Med. 2014;14:267. https://pubmed.ncbi.nlm.nih.gov/25066015/
[54] Cuellar NG, Ratcliffe SJ. "Does valerian improve sleepiness and symptom severity in people with restless legs syndrome?" Altern Ther Health Med. 2009;15(2):22-28. https://pubmed.ncbi.nlm.nih.gov/19284179/
[55] Winkelman JW, Berkowski JA, DelRosso LM, et al. "Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline." J Clin Sleep Med. 2025;21(1):137-152. https://pubmed.ncbi.nlm.nih.gov/39324694/
[56] Mirabi P, Mojab F. "The effects of valerian root on hot flashes in menopausal women." Iran J Pharm Res. 2013;12(1):217-222. https://pubmed.ncbi.nlm.nih.gov/24250592/
[63] Kuhlmann J, Berger W, Podzuweit H, Schmidt U. "The influence of valerian treatment on 'reaction time, alertness and concentration' in volunteers." Pharmacopsychiatry. 1999;32:235-241. https://pubmed.ncbi.nlm.nih.gov/10599933/
[64] Bounthanh C, Bergmann C, Beck JP, Haag-Berrurier M, Anton R. "Valepotriates, a new class of cytotoxic and antitumor agents." Planta Med. 1981;41:21-28. https://pubmed.ncbi.nlm.nih.gov/7232547/
[65] Bounthanh C, Richert L, Beck JP, Haag-Berrurier M, Anton R. "The action of valepotriates on the synthesis of DNA and proteins of cultured hepatoma cells." Planta Med. 1983;49:138-142. https://pubmed.ncbi.nlm.nih.gov/6657786/
[66] Tufik S, Fujita K, Seabra ML, Lobo LL. "Effects of a prolonged administration of valepotriates in rats on the mothers and their offspring." J Ethnopharmacol. 1994;41:39-44. https://pubmed.ncbi.nlm.nih.gov/8170157/
[68] MacGregor FB, Abernethy VE, Dahabra S, Cobden I, Hayes PC. "Hepatotoxicity of herbal remedies." BMJ. 1989;299:1156-1157. https://pubmed.ncbi.nlm.nih.gov/2513032/
[71] Garges HP, Varia I, Doraiswamy PM. "Cardiac complications and delirium associated with valerian root withdrawal." JAMA. 1998;280:1566-1567. https://pubmed.ncbi.nlm.nih.gov/9820254/
[73] Willey LB, Mady SP, Cobaugh DJ, Wax PM. "Valerian overdose: a case report." Vet Hum Toxicol. 1995;37:364-365. https://pubmed.ncbi.nlm.nih.gov/8540231/
[74] European Scientific Cooperative on Phytotherapy. "Valerianae radix: valerian root." In: Monographs on the Medicinal Uses of Plant Drugs. Exeter, UK: ESCOP, 1997: 1-10.
[76] Ang-Lee MK, Moss J, Yuan CS. "Herbal medicines and perioperative care." JAMA. 2001;286(2):208-216. https://pubmed.ncbi.nlm.nih.gov/11448284/
[77] Natural Medicines Comprehensive Database. "Valerian." 2013.
[80] Donovan JL, DeVane CL, Chavin KD, et al. "Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers." Drug Metab Dispos. 2004;32(12):1333-1336. https://pubmed.ncbi.nlm.nih.gov/15328251/
[86] Santos MS, Ferreira F, Cunha AP, Carvalho AP, Macedo T. "An aqueous extract of valerian influences the transport of GABA in synaptosomes." Planta Med. 1994;60:278-279. https://pubmed.ncbi.nlm.nih.gov/8073095/
[88] Krieglstein VJ, Grusla D. "Central depressing components in Valerian: Valeportriates, valeric acid, valerone, and essential oil are inactive, however [in German]." Deutsche Apotheker Zeitung. 1988;128:2041-2046.
[91] Taibi DM, Vitiello MV, Barsness S, et al. "A randomized clinical trial of valerian fails to improve self-reported, polysomnographic, and actigraphic sleep in older women with insomnia." Sleep Med. 2009;10(3):319-328. https://pubmed.ncbi.nlm.nih.gov/18482867/
[92] National Institute of Diabetes and Digestive and Kidney Diseases. "Valerian." In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda, MD: NIDDK, 2012. https://pubmed.ncbi.nlm.nih.gov/31643579/
[93] Cohen DL, Del Toro Y. "A case of valerian-associated hepatotoxicity." J Clin Gastroenterol. 2008;42(8):961-962. https://pubmed.ncbi.nlm.nih.gov/18431248/
[94] Kia YH, Alexander S, Dowling D. "A case of steroid-responsive valerian-associated hepatitis." Intern Med J. 2016;46(1):118-119. https://pubmed.ncbi.nlm.nih.gov/26813905/
[95] Gerhard U, Linnenbrink N, Georghiadou C, et al. "Vigilance-decreasing effects of 2 plant-derived sedatives [in German]." Praxis (Bern 1994). 1996;85(15):473-481. https://pubmed.ncbi.nlm.nih.gov/8657986/
[96] Thomas K, Canedo J, Perry PJ, et al. "Effects of valerian on subjective sedation, field sobriety testing and driving simulator performance." Accid Anal Prev. 2016;92:240-244. https://pubmed.ncbi.nlm.nih.gov/27110643/
[97] Bao H, Pan X, Tao Q, et al. "Safety evaluation of aqueous extract from Valeriana officinalis L. roots: genotoxicity, acute, subchronic and teratology toxicity." J Ethnopharmacol. 2024;335:118687. https://pubmed.ncbi.nlm.nih.gov/39128798/



